Executive VP, Global R&D Fridriksdottir Hafrun sold 1,643 shares in Teva Pharmaceutical Industries Limited (NYSE:TEVA) for $11,826 in transaction occurred on 2019/01/02. After making this transaction, the Executive VP, Global R&D owns a direct stake of 25,795 shares, worth $218,190, as per the last closing price. On 2018/11/30 Fridriksdottir Hafrun, Executive VP, Global R&D at TEVA, dumped 933 shares at an average price of $21.76 per share. The selling total is valued at $162,895.

Separately, it had been reported that some other TEVA insiders also took part of the insider trading activity. EVP, CFO, Mcclellan Michael James had divested 346 shares for $11,644 through a trade on 2018/11/05. Following this activity, the insider holds 7,865 shares worth $214,832 as of recent close. Wall Street’s most bullish Teva Pharmaceutical Industries Limited (NYSE:TEVA) analysts are predicting the share price to blow past $30 per share during the next 12 months. The current median share price forecast by them is $24, suggesting that the stock could increase 30.08% in that time frame. The average price target of $22.71 calls for a nearly 23.09% increase in the stock price.

Teva Pharmaceutical Industries Limited (TEVA) trading activity significantly weakened as the volume at ready counter decreased to 8,562,237 shares versus 13,414,750 in average daily trading volume over the past 20 days. So far this year, the volume has averaged about 10,548,649 shares. The share price rose 1.54% in recent trade and currently has a stock-market value of $19.52B. The shares finished at $18.45, after trading as low as $18.1301 earlier in the session. It hit an intraday high Friday at $18.53. The stock is now 26.46% above against its bear-market low of $14.59 on December 24, 2018. It has retreated -40.7% since it’s 52-week high of $25.96 reached in August. Now the market price is down -7.93% on the year and up 19.65% YTD.

TEVA’s 50 day simple moving average (SMA 50) price is $19.75 and its 200-day simple moving average (SMA 200) price is $21.17. The company’s stock currently has a total float of 1.05B shares. Its weekly volatility is hovering around 3.95% and felt 4.59% volatility in price over a month. On the upside, the share price will test short term resistance at around $18.61. On a downside, the stock is likely to find some support, which begins at $18.21. The failure to get near-term support could push it to $17.97.

It had seen a positive analyst call from BofA/Merrill, which upgraded the stock from Underperform to Buy on January 03. Analysts at Morgan Stanley, shed their negative views on November 05 by lifting it fromEqual-Weight to Overweight. The stock won favor of Leerink Partners analysts who expressed their confidence in it using an upgrade from Underperform to Mkt Perform on October 01.

Moreover, it trades for 6.52 times the next 12 months of expected earnings. Also, it is trading at rather expensive levels at just over 1.35x price/book and 0.99x price/sales. Compared to others, Teva Pharmaceutical Industries Limited is in a different league with regards to profitability, having net margins of -56%. To put some perspective around this, the industry’s average net margin is 5.44%. TEVA’s ROE is -78%, which is also considerably worse than the industry’s ROE of 15.85%. It’s also not liquid in the near term, with a current ratio of 0.9. The stock has a debt/capital of 2.12.

Shares of Teva Pharmaceutical Industries Limited (TEVA) have dropped -7.7% since the company’s Mar-19 earnings report. Over the past 12 fiscal quarters, Teva Pharmaceutical Industries Limited (NYSE:TEVA) has topped consensus earnings estimates in 7 quarters (58%), missed earnings in 2 quarters (16%), whereas at 3 occasion EPS met analyst expectations. TEVA last reported earnings on November 01, 2018 when it released Sep-18 results that exceeded expectations. The company raked in $0.68 per share, -97.37% change on the same period last year. That was better than consensus for $0.54. Revenue for the recent quarter stood at $4.53 billion, down -19% on last year and below the $4.53 billion predicted by analysts. For this quarter, Wall Street analysts forecast revenue in a range of $4.46 billion to $4.72 billion, which should be compared with $5.01 billion generated last year. EPS is seen in a range of $0.63 to $0.72, against the $0.78 reported a year ago.